Drug Research
Chembio Announces Launch of DPP COVID-19 Serological Point-of-Care Test
Chembio Diagnostics, Inc. , a leading point-of-care diagnostic company focused on infectious diseases, announced the U.S. launch of the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies. These results can be obtained within...
Clinical Trials
PHARMASEAL Supports Life Science Businesses by Offering No Cost CTMS for COVID-19 Clinical Trials
PHARMASEAL International, provider of clinical trials management systems has announced that it will offer the Engility® CTMS solution at no cost for COVID-19 Coronavirus clinical trials. The free offer to utilize Engility CTMS is open to biopharmaceutical organizations and...
Drug Research
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
Eli Lilly and Company announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical...
Press Releases
Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus
Covalon Technologies Ltd , an advanced medical technologies company, announces its new breakthrough antimicrobial technology formulated to kill the COVID-19 virus (or “SARS-CoV-2”) and other viruses, bacteria, and pathogens.
The new technology, called CovaGuard™, has been specifically formulated to be...
Press Releases
Cobra Bio Secures $3.3 Million to Develop DNA Vaccine Against COVID-19
U.K.-based Cobra Biologics and noted medical university the Karolinska Institute, which is based in Sweden, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA...
Press Releases
GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy
GigaGen is developing a recombinant polyclonal antibody therapy (rCIG) to treat COVID-19. First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
“We are working toward an...
Press Releases
ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines
Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, announced a strategic partnership with clinical data company WideTrial to facilitate greater access to investigational medicines for physicians and patients dealing with COVID-19 worldwide.
The project’s objective is to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.